Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis(GHOA)

Prospective, Double Blind, Randomized Control Trial Comparing the Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04949087

Acronym

GHOA

Enrollment

200

Registered

2021-07-02

Start date

2023-03-13

Completion date

2028-01-01

Last updated

2026-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis Shoulder

Brief summary

The purpose of this study is to compare the efficacy of intra-articular corticosteroid injections versus platelet-rich plasma injections for non-operative treatment of primary glenohumeral osteoarthritis. The efficacy of intra-articular injections, outside of hyaluronic acid, for the treatment of glenohumeral OA is not known, yet these treatments are commonly used with hopes of providing patients with symptomatic relief that can hopefully delay or prevent the need for shoulder arthroplasty. This study will help elucidate the therapeutic benefit of corticosteroid and Platelet Rich Plasma (PRP) injections in this patient population.

Interventions

PROCEDUREGlenohumeral Injection

Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Masking description

Double-blinded, randomized

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient ≥18y.o. of age * Primary glenohumeral arthritis (bone on bone or near bone on bone) that has been previously diagnosed on radiographs and clinical evaluation. * Baseline pain level of VAS \>4

Exclusion criteria

* Secondary causes of arthritis (i.e. septic arthritis, rheumatoid arthritis, rotator cuff arthropathy, post-traumatic arthritis) * Ipsilateral shoulder surgery within 1 year * Any glenohumeral joint injection within 3 months * Allergy to lidocaine * Known pregnancy * Workers compensation case regarding shoulder

Design outcomes

Primary

Measure	Time frame	Description
Visual Analog Scale-Pain (VAS)	12 weeks	Validated patient-reported metric scale of pain: no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm)

Countries

United States

Contacts

CONTACTCarla M Edwards, PhD

carla_edwards@rush.edu312.563.5735

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026